Biomarkers for diagnosis of myocardial infarction

Abstract

Introduction: It is well known that myocardial infarction is a significant cause of deaf. Annually, several million patients seek care in the emergency department because of chest pain or other symptoms suggesting an acute coronary syndrome (ACS), but only about 10% are subsequently confirmed to have acute myocardial infarction (AMI). Current cardiac marker technologies can detect extremely small amounts of myocardial necrosis (<1.0 g). Blood testing for biomarkers of myocardial injury plays an increasingly important role for the evaluation, diagnosis, and triage of patients with chest pain. Materials and methods: This study was aimed for comparative analysis of cardiac biomarkers and argumentation of their use for early diagnosis of myocardial infarction. The study included 120 patients, hospitalized in the Intensive Care Unit of Cardiology Clinic, from whos were taken three blood samples for biochemical analysis (within 24 hours after admission, over 10 days (the discharge) and over 2 months). Results: The research showed that cardiac biomarkers should be measured in all patients who present with chest discomfort consistent with acute coronary syndrome (ACS). Elevations of cardiac enzyme levels should be interpreted in the context of clinical and ECG findings. Conclusions: Cardiac troponins T and I are the preferred markers for myocardial injury as they have the highest sensitivity and specificity for the diagnosis of acute myocardial infarction. Presence of any cardiac troponin indicates a worse prognosis in patients with coronary artery disease. At the present time it appears undesirable to attempt to use hs-CRP and B-type natriuretic peptide in individual risk stratification